| Description | Quazolast (RHC 3988) is a potent mediator release inhibitor and is a control against ragweed antigenic nasal challenge. quazolast is superior to placebo in preventing nasal congestion and nasal itching following ragweed nasal challenge. |
| In vivo | Quazolast（口服400 mg；针对RW过敏；23名受试者）在1350和2700 PNU时，导致的鼻腔流量平均百分比降低显著低于（P小于.05）对照组。在1000、1350和2700 PNU的剂量下，Quazolast治疗期间鼻痒评分显著低于（P小于.05）安慰剂。[1] |
| Synonyms | RHC-3988, RHC 3988, RHC3988 |
| molecular weight | 262.65 |
| Molecular formula | C12H7ClN2O3 |
| CAS | 86048-40-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 2.63 mg/mL (10 mM), Sonication is recommended. |
| References | 1. Dave NK, et al. A controlled, double-blind study of the effect of quazolast on nasal challenge with ragweed antigen. Ann Allergy. 1990 ; 65(4):298-302. 2. Fitzpatrick LR, et al. Gastroprotective and ulcer healing profile of the mast cell stabilizer quazolast in rats. Agents Actions. 1991 ; 33(3-4):330-336. |